Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AURA vs VIR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VIR Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

VIR Overall Winner 6-Pillar Tally: AURA 2 – 4 VIR Matrix Metrics: AURA 4 – 6 VIR

As of Nov 16, 2026, Vir Biotechnology, Inc. (VIR) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). AURA carries a Unified Composite Score of 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas VIR carries 41.6/100 (SELL) at $9.76 (4.3x Forward P/E, -70.2% operating margin).

  • Defensive Composite Rating Caution: Although VIR compares more favorably head-to-head, both AURA (28.8/100 SELL) and VIR (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7); meanwhile VIR is in a Breakdown options structure phase (RSI 39.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AURA vs VIR
AURA NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 50.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.7 · SMA20: $6.66 · SMA50: $6.54
VIR NASDAQ Head-to-Head Winner
Vir Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.76
-2.01% 1D
Market Cap $2.1B
TTM Revenue $303M
Forward P/E 4.3x
Beta / 30D Vol 1.71β · 102% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 20.0 Fund 46.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.6 · SMA20: $11.44 · SMA50: $11.11

6-Pillar Scorecard Institutional Category Breakdown (AURA 2 – 4 VIR)

Columns: Metric · AURA · VIR
1. Valuation Multiples VIR
Forward P/E N/M 4.3x
Trailing P/E N/M 4.3x
PEG Ratio N/M N/M
EV / Revenue N/M 6.4x
2. Growth & Scale VIR
Revenue Growth (YoY) +0.0% +19582.5%
Earnings Growth (YoY) +0.0% +58.5%
TTM Revenue (USD) N/A $303M
Market Cap $728.6M $2.1B
3. Profitability & Quality AURA
Gross Margin N/A -36.7%
Operating Margin 0.0% -70.2%
Net Profit Margin 0.0% -61.0%
Return on Equity (ROE) -61.7% -21.8%
4. Balance Sheet & Cash Flow VIR
Cash Generation (TTM) -$110M -$142M
Cash Flow Margin N/A -46.8%
Net Cash / Leverage $26M Net Cash $128M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 160.1% (22nd %ile) 69.6% (6th %ile)
Put/Call OI Skew N/A 0.20x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat VIR
OpEx & R&D Intensity N/A 33.5% of Rev ($101M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AURA (4) vs VIR (6)
Institutional Metric AURA VIR Criterion Row Edge
Market Capitalization
Scale
$728.6M $2.1B Larger Scale VIR
Trailing P/E Ratio
Valuation
N/M 4.3x Lower Multiple VIR
Forward P/E Ratio
Valuation
N/M 4.3x Lower Multiple VIR
Revenue Growth (YoY)
Growth
+0.0% +19582.5% Higher Growth VIR
Operating Margin (TTM)
Profitability
0.0% -70.2% Higher Margin AURA
Net Profit Margin
Profitability
0.0% -61.0% Higher Margin AURA
Return on Equity (ROE)
Capital Efficiency
-61.7% -21.8% Higher ROE VIR
52-Week Range Position
Momentum
52% ($5–$10) 49% ($5–$14) Stronger Trend AURA
Beta / 30D Volatility
Risk Regime
0.92β · 75% Vol 1.71β · 102% Vol Lower Realized Risk AURA
Unified Institutional Score
Composite Signal
28.8 / 100 (SELL) 41.6 / 100 (SELL) Higher Composite VIR
Trailing 12M Revenue (USD)
Operating Scale
N/A $303M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -36.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($26M Net Cash) -$142M ($128M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AURA +20.21 pp
AURA: +18.2% · VIR: -2.01%
3M Horizon VIR +14.49 pp
AURA: -11.64% · VIR: +2.85%
6M Horizon VIR +14.77 pp
AURA: -3.48% · VIR: +11.29%
1Y Horizon VIR +48.05 pp
AURA: +30.38% · VIR: +78.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs VIR. Trailing 12-month operating profitability (AURA 0.0% vs VIR -70.2%) and valuation multiples (AURA N/M vs VIR 4.3x Forward P/E) are benchmarked directly in Pillar 4 below.

AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M
VIR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$303M
Gross Margin-36.7%
Op. Margin-70.2%
ROE / Fwd P/E-21.8% · 4.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VIR BREAKDOWN
5d in phase · OBV DISTRIBUTION
Current IV 69.6%
IV Percentile 6th %ile
Put/Call OI Skew 0.20x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact VIR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VIR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -70.2% operating margin.
OpEx & R&D Reinvestment 33.5% of Rev ($101M)
90D Engineering Disclosures 0 Published

Investor FAQ AURA vs VIR Key Questions & Quantitative Answers

As of Nov 16, 2026, Vir Biotechnology, Inc. (VIR) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). AURA carries a Unified Composite Score of 28.8/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas VIR carries 41.6/100 (SELL) at $9.76 (4.3x Forward P/E, -70.2% operating margin). Defensive Composite Rating Caution: Although VIR compares more favorably head-to-head, both AURA (28.8/100 SELL) and VIR (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AURA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 58.7); meanwhile VIR is in a Breakdown options structure phase (RSI 39.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VIR leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VIR at +19582.5% YoY revenue growth and +58.5% YoY earnings growth on $303M TTM revenue (-36.7% gross margin, -70.2% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $303M for VIR. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus 33.5% of Rev ($101M) (0 disclosures) for VIR.

VIR screens cheaper on headline valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VIR trades at 4.3x Forward P/E, 4.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-46.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus VIR (-21.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, VIR carries 69.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.20x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.71β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.